PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Pfizer Validates Coley Pharmaceutical's ProMune™ with Deal Worth US$515 M Plus
From issue 59 of the PharmaDeals Review (2005-05-01)
In what would be the largest value licensing deal of 2005 so far, Pfizer has agreed to develop, manufacture and commercialise Coley Pharmaceutical Group's Phase II oligonucleotide therapeutic, ProMune™ (CpG 7909), which has broad applicability as an anticancer therapy. This article examines the motivations of both companies for signing the deal.
Available as PDF
(Subscribers only)
Abbott Takes First Pick at BioCurex
From issue 59 of the PharmaDeals Review (2005-05-01)
The recent deal between diagnostics giant Abbott Laboratories and the small Canadian company BioCurex sent a wave of excitement through industry observers and investors. The reaction stemmed from the realisation of the enormousness of the deal for BioCurex in terms of the potential future prospects that the partnership brings.
Available as PDF
(Subscribers only)
Deal Making Trends of Top Pharma Companies
From issue 59 of the PharmaDeals Review (2005-05-01)
This article is adapted from PharmaVentures' recent report Facts and Trends in Deal Making: A Perspective on the Pharma and Biotech Industries. It examines the deal making preferences of five companies (Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca and Johnson & Johnson) over the past 8 years (1997-2004), so as to gain insight into their strategies.
Available as PDF
(Subscribers only)
Therapy Focus: Erectile Dysfunction
From issue 59 of the PharmaDeals Review (2005-05-01)
Pfizer's Viagra®, the first oral drug treatment for erectile dysfunction (ED), has established itself rapidly as a blockbuster product. This feature reviews Viagra's current performance and investigates the ED market following the launch of the second generation of phosphodiesterase-5 inhibitors in 2003.
Available as PDF
(Subscribers only)
Takeda and 3M Target HPV and Future Growth
From issue 58 of the PharmaDeals Review (2005-04-01)
By signing up Takeda Pharmaceutical to co-develop and market jointly one of its proprietary immune response modifiers (IRMs) for high-risk human papillomavirus (HPV) infection and cervical dysplasia, 3M is aiming to commercialise a follow-up to the successful Aldara® Cream 5% (imiquimod). Takeda's motives are similarly forward thinking.
Last Issue PDF
RSS